Truist Financial Corp raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 81.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,996 shares of the company’s stock after purchasing an additional 2,699 shares during the period. Truist Financial Corp’s holdings in CRISPR Therapeutics were worth $392,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of the business. Allworth Financial LP grew its stake in shares of CRISPR Therapeutics by 21.0% during the second quarter. Allworth Financial LP now owns 737 shares of the company’s stock valued at $45,000 after buying an additional 128 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of CRISPR Therapeutics by 8.2% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,944 shares of the company’s stock valued at $118,000 after buying an additional 148 shares during the last quarter. HC Advisors LLC grew its stake in shares of CRISPR Therapeutics by 2.1% during the second quarter. HC Advisors LLC now owns 7,432 shares of the company’s stock valued at $452,000 after buying an additional 154 shares during the last quarter. Bouvel Investment Partners LLC grew its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. Bouvel Investment Partners LLC now owns 18,726 shares of the company’s stock valued at $1,224,000 after buying an additional 190 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of CRISPR Therapeutics by 3.0% during the second quarter. Cetera Investment Advisers now owns 8,064 shares of the company’s stock valued at $490,000 after buying an additional 237 shares during the last quarter. Institutional investors own 71.51% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. EF Hutton Acquisition Co. I assumed coverage on CRISPR Therapeutics in a research note on Thursday, January 5th. They set a “buy” rating and a $75.00 target price on the stock. Citigroup dropped their price objective on CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 23rd. Morgan Stanley began coverage on CRISPR Therapeutics in a research note on Tuesday, October 11th. They issued an “underweight” rating and a $37.00 price objective on the stock. Barclays dropped their price objective on CRISPR Therapeutics from $88.00 to $61.00 in a research note on Wednesday, November 2nd. Finally, Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $79.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 2nd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $98.22.
CRISPR Therapeutics Trading Up 1.2 %
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($2.24) EPS for the quarter, beating the consensus estimate of ($2.30) by $0.06. CRISPR Therapeutics had a negative return on equity of 31.34% and a negative net margin of 4,831.79%. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $3.53 million. As a group, research analysts forecast that CRISPR Therapeutics AG will post -9.25 EPS for the current year.
Insider Buying and Selling
In related news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $40.93, for a total value of $1,023,250.00. Following the completion of the transaction, the chief executive officer now owns 369,111 shares in the company, valued at approximately $15,107,713.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.30% of the stock is currently owned by company insiders.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.